{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:27:41Z","timestamp":1787120861264,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Antibody\u2013drug conjugates (ADCs) have established roles in selected lymphoma settings, but the maturity, subtype distribution, and platform diversity of the clinical pipeline remain unclear. We mapped interventional trials to evaluate development trends, evidence maturity, molecular architecture, combination strategies, inactive development, and safety reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched Trialtrove for Phase I\u2013IV interventional trials evaluating at least one ADC in lymphoma, with actual or anticipated start dates through December 31, 2025. Non-ADC studies, observational studies, trials without lymphoma populations, and records with unconfirmed eligibility were excluded. Two reviewers independently screened and classified eligible records, with external verification when available. Analyses were descriptive; treatment effects and patient-level adverse-event incidences were not pooled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 482 records, 410 trials were included. Phase II was the largest category (193, 47.1%); 253 trials (61.7%) were single-arm and 76 (18.5%) were randomized. Among 837 trial\u2013subtype pairs, diffuse large B-cell lymphoma (213, 25.4%) and classical Hodgkin lymphoma (135, 16.1%) were the most frequent and contained most late-phase activity. CD30 (181 trials), CD79b (104), CD19 (47), and CD22 (29) were the leading assigned targets. Of 50 unique ADC programs, 35 (70.0%) had not progressed beyond Phase I or Phase I\/II. Tubulin inhibitors and cleavable linkers predominated. Among 92 inactive trials, the leading reported categories were recruitment or feasibility problems (30), unspecified reasons (28), and sponsor strategy (15). In 177 safety-evaluable trials, grade \u22653 adverse events were reported in 109, neutropenia in 98, infection in 79, and peripheral neuropathy in 69.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Lymphoma ADC development has expanded, but trial growth has outpaced platform diversification and the generation of confirmatory evidence. Mature development remains concentrated in DLBCL, cHL, and a limited number of target\u2013payload\u2013linker platforms, while randomized, survival-based, and biomarker-driven evidence remains limited. Future priorities include subtype-specific targeting, platform diversification, randomized comparative studies, standardized safety reporting, biomarker-guided patient selection, and rational sequencing with immune and cellular therapies. Trial status and trial-level safety-reporting frequencies should not be interpreted as measures of clinical success or patient-level adverse-event incidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1855476","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:46:41Z","timestamp":1787118401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody\u2013drug conjugate development in lymphoma: a systematic clinical trial landscape analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hengrui","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxi","family":"Yan","sequence":"additional","affiliation":[{"name":"School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7056","article-title":"Global burden, risk factors, and trends of non-Hodgkin lymphoma: a worldwide analysis of cancer registries","volume":"13","author":"Huang","year":"2024","journal-title":"Cancer Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33948","article-title":"Global patterns of Hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040","volume":"150","author":"Singh","year":"2022","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00970-z","article-title":"Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands","volume":"14","author":"Pennings","year":"2024","journal-title":"Blood Cancer J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2352086","article-title":"Mitigating time toxicity in lymphoma and multiple myeloma","volume":"65","author":"Di","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013drug conjugates: current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00925","article-title":"Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma","volume":"43","author":"Morschhauser","year":"2025","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283459","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000001065","article-title":"Update of antibody\u2013drug conjugates for hematological Malignancies","volume":"36","author":"Sun","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody\u2013drug conjugates: strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist Update"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0802","article-title":"Molecular determinants of sensitivity to polatuzumab vedotin in diffuse large B-cell lymphoma","volume":"14","author":"Corcoran","year":"2024","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B-cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting cancer with antibody\u2013drug conjugates: promises and challenges","volume":"13","author":"Dean","year":"2021","journal-title":"MAbs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2453524","article-title":"The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma","volume":"25","author":"Ahmed","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02242","article-title":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104241","article-title":"Antibody\u2013drug conjugates: prospects for the next generation","volume":"29","author":"Grairi","year":"2024","journal-title":"Drug Discov Today"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1039\/D3MD00674C","article-title":"The medicinal chemistry evolution of antibody\u2013drug conjugates","volume":"15","author":"Hobson","year":"2024","journal-title":"RSC Med Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2024.2339993","article-title":"Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer","volume":"54","author":"Moore","year":"2024","journal-title":"Xenobiotica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody-drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"Biomedicines"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156341","article-title":"Unraveling ADC resistance in hematologic Malignancies: challenges and new frontiers","volume":"278","author":"Armanious","year":"2026","journal-title":"Pathol Res Pract"},{"key":"B29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.20517\/cdr.2025.148","article-title":"Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies","volume":"8","author":"Hao","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071491","article-title":"Antibody-drug conjugates to promote immune surveillance: lessons learned from breast cancer","volume":"12","author":"Nucera","year":"2024","journal-title":"Biomedicines"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2533488","article-title":"Immunogenic cell death and bystander killing","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27021025","article-title":"Antibody-drug conjugates in hematological Malignancies: current landscape and future perspectives","volume":"27","author":"Montalbano","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab plus AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101140","article-title":"A paradox of choice: sequencing therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"63","author":"Brooks","year":"2024","journal-title":"Blood Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1855476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:46:43Z","timestamp":1787118403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1855476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2026.1855476"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1855476","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1855476"}}